Stoneridge Investment Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Stoneridge Investment Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-24,076	Closed	-$313K	–	196
2018 Q1	$313K	Buy	24,076 +12,442	+107%	+$185K	0.05%	153
2017 Q4	$208K	Hold	11,634	–	–	0.03%	197
2017 Q3	$292K	Buy	+11,634	New	+$271K	0.05%	182
2017 Q2	–	Sell	-20,411	Closed	-$393K	–	324
2017 Q1	$393K	Sell	20,411 -7,699	-27%	-$121K	0.05%	232
2016 Q4	$433K	Buy	28,110 +374	+1%	+$4.86K	0.06%	231
2016 Q3	$361K	Buy	27,736 +4,068	+17%	+$53.9K	0.05%	227
2016 Q2	$329K	Buy	+23,668	New	+$348K	0.05%	228

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stoneridge Investment Partners's PRTK Position: Q2 2018 in Review

Stoneridge Investment Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2018, closing a stake of 24,076 shares — an estimated $313K sold.

Stoneridge Investment Partners first reported a position in PRTK in Q2 2016 and held it in 7 quarters. The position peaked at $433K in Q4 2016. 110 funds tracked by Wall St. Rank hold PRTK as of Q2 2018.

Stoneridge Investment Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Stoneridge Investment Partners sold 24,076 Paratek Pharmaceuticals, Inc. shares in Q2 2018, an estimated $313K.
Stoneridge Investment Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 7 quarters.
Stoneridge Investment Partners's Paratek Pharmaceuticals, Inc. position peaked at $433K in Q4 2016.
110 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2018.

Based on Stoneridge Investment Partners's 13F filing for Q2 2018, filed 31 Jul 2018.